Back to Search
SHAWN MOULDER, D.O.
D.O.
Surgery Physician
NPI: 1770964496IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
5101022023(MI)
CMS Specialties
PrimaryGENERAL SURGERY
Education
KANSAS CITY UNIVERSITY OF MED & BIOSCIENCES, COLLEGE OF OSTEO MED
Class of 2015
Research & Publications (18)
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
PMID 19499186·Invest New Drugs·2010
3-trial
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
PMID 19204084·Mol Cell Biol·2009
7-preclinical
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
PMID 19351752·Clin Cancer Res·2009
3-trial
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
PMID 19596702·Ann Oncol·2009
8-other
Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
PMID 18537531·Anticancer Agents Med Chem·2008
6-review
Ixabepilone for the treatment of taxane-refractory breast cancer.
PMID 18518758·Future Oncol·2008
6-review
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
PMID 19047121·Clin Cancer Res·2008
3-trial
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
PMID 18829509·Clin Cancer Res·2008
3-trial
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
PMID 18823053·Cancer·2008
3-trial
Improving the institutional submission and approval process for clinical research protocols in oncology.
PMID 17443009·J Clin Oncol·2007
8-other
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
PMID 17317835·Clin Cancer Res·2007
3-trial
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
PMID 16769985·J Clin Oncol·2006
3-trial
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
PMID 15534083·Clin Cancer Res·2004
3-trial
A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
PMID 12864943·Clin Breast Cancer·2003
3-trial
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.
PMID 12138392·Semin Oncol·2002
6-review
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
PMID 11751413·Cancer Res·2001
7-preclinical
Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity.
PMID 11561987·Semin Urol Oncol·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 18101 OAKWOOD BLVD
DEARBORN, MI 48124 - Phone
- (313) 593-7000
Quick Facts
- NPI
- 1770964496
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 11
- Publications
- 18
Are you this provider?
Claim Your Profile